[Pre-neoplastic bronchial lesions: possibilities of diagnosis and chemo-prevention].
Early diagnosis of pulmonary cancer is crucial in the fight against this disease. Pre-neoplastic bronchial lesions are the first stage in the evolution towards invasive cancers. This paper describes histological patterns of these pre-neoplastic bronchial lesions, as well as early, intermediate and late molecular disturbances associated with this condition. The ways to early identification of these lesions are: a) bronchoscopy with laser-induced auto-fluorescence guided through Optical Coherence Tomography, which is able to identify cellular and extracellular structures, from the cellular surface or beneath it; b) PET-CT which identifies lesions over 6 mm; c) bio-markers: the sensitivity of the test is 60-70%; the positive predictive value is higher when these markers are taken together. p53 and p16-INK4A genes seem to have the higher predictive value. Identification of these disturbances leads to improved possibilities of chemo-prevention.
Popescu
Iulian
I
Secţia clinică de Radio-biologie, Spitalul Clinic Fundeni, Bucureşti. popdociul@yahoo.com
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D014408:Biomarkers, Tumor / Q000378:metabolism; D018893:Bronchoalveolar Lavage; D001999:Bronchoscopy / Q000379:methods; D000068818:Cetuximab; D042241:Early Diagnosis; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D019942:Genes, p16; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D008403:Mass Screening; D009154:Mutation; D049268:Positron-Emission Tomography; D011230:Precancerous Conditions / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology*; D011237:Predictive Value of Tests; D011799:Quinazolines / Q000008:administration & dosage; D012680:Sensitivity and Specificity; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011799:Quinazolines; D016159:Tumor Suppressor Protein p53; D000068258:Bevacizumab; D000069347:Erlotinib Hydrochloride; D000068818:Cetuximab; D000077156:Gefitinib